Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Vet Diagn Invest ; 33(1): 87-94, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33225861

ABSTRACT

CD71 is an immunohistochemical marker used in diagnosing acute myeloid leukemia (AML) M6-Er in humans; however, to our knowledge, it has not been reportedly used for immunohistochemistry in veterinary medicine. We evaluated the pathologic features of AML M6-Er in a retrovirus-negative cat and used CD71 to support the diagnosis. A 4-y-old spayed female Scottish Fold cat was presented with lethargy, anorexia, and fever. Whole-blood PCR assay results for pro feline leukemia virus/pro feline immunodeficiency virus and feline vector-borne diseases were negative. Early erythroid precursors were observed in the peripheral blood smear. Fine-needle aspiration of the enlarged spleen and splenic lymph node showed many early erythroid precursors. Bone marrow aspirate smears revealed erythroid hyperplasia with 68.4% erythroid lineage and 3.6% rubriblasts. Dysplastic cells infiltrated other organs. The patient was diagnosed with myelodysplastic syndrome, progressing to the early phase of AML M6-Er. The patient died on day 121 despite multidrug treatments. Postmortem examination revealed neoplastic erythroblasts infiltrating the bone marrow and other organs. Neoplastic cells were immunopositive for CD71 but immunonegative for CD3, CD20, granzyme B, von Willebrand factor, CD61, myeloperoxidase, and Iba-1. Although further studies are necessary for the application of CD71, our results supported the morphologic diagnosis of AML M6-Er.


Subject(s)
Antigens, CD/blood , Cat Diseases/diagnosis , Leukemia Virus, Feline/isolation & purification , Leukemia, Erythroblastic, Acute/veterinary , Receptors, Transferrin/blood , Animals , Biomarkers, Tumor/blood , Bone Marrow/pathology , Cat Diseases/blood , Cats , Diagnosis, Differential , Female , Immunohistochemistry/veterinary , Leukemia, Erythroblastic, Acute/diagnosis , Retroviridae/immunology
2.
Prostaglandins Other Lipid Mediat ; 94(3-4): 118-23, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21376132

ABSTRACT

To explore the mechanism for anti-ovulatory effects of blockade of preovulatory synthesis and action of progesterone, we focused on cyclooxygenase (COX)-2 induction and mitotic activity of granulosa cells in gonadotropins-treated rats. Treatment with RU486 (a progesterone receptor antagonist) or trilostane (a 3ß-hydroxysteroid dehydrogenase inhibitor) just prior to or 4h after human chorinonic gonadotropin (hCG) (hCG4h) decreased ovulation rates and circulating progesterone level. Human CG induction of immunoreactive COX-2 in the granulosa layer of mature Graafian follicles at hCG8h was reduced by RU486 treatment at hCG0h and trilostane treatment at hCG4h. RU486 treatment further attenuated ovarian prostaglandin E(2) (PGE(2)) level significantly. Cell proliferative activity in mural granulosa layer of the inhibitors-treated follicles was significantly lower than in intact group. Obtained results show that inhibition of synthesis and action of progesterone caused attenuated COX-2/PGE(2) system and dysregulated mitotic response of granulosa cells, resulting in decreased ovulation.


Subject(s)
Cyclooxygenase 2/biosynthesis , Dihydrotestosterone/analogs & derivatives , Mifepristone/pharmacology , Ovulation/drug effects , Ovulation/metabolism , Animals , Chorionic Gonadotropin/antagonists & inhibitors , Chorionic Gonadotropin/metabolism , Cyclooxygenase 2/genetics , Dihydrotestosterone/pharmacology , Dinoprostone/antagonists & inhibitors , Female , Granulosa Cells/cytology , Granulosa Cells/drug effects , Humans , Mitosis/drug effects , Mitosis/genetics , Ovarian Follicle/cytology , Ovarian Follicle/drug effects , Progesterone/antagonists & inhibitors , Progesterone/biosynthesis , Progesterone/blood , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL